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Abstract
Background: Paediatric drug formulations for artemisinin combination therapy (P-ACT) have been developed over the
past few years and have been shown to improve the therapeutic management of young children with uncomplicated
falciparum malaria. This process was however not equally paralleled by a timely adoption of P-ACT in national and
international treatment recommendations. National malaria programmes in sub-Saharan Africa have not yet widely
embraced this new therapeutic tool. To which extent P-ACT is used in the field in sub-Saharan Africa is not known to date.
Methods: This snapshot questionnaire survey aimed to provide an overview on the current routine practices for
the availability and use of P-ACT as anti-malarial treatment for young children in sub-Saharan Africa. Health care
personnel in seven countries in West-, Central, and East-Africa were invited to answer a structured questionnaire
assessing use and availability of P-ACT.
Results: A total of 71 respondents including doctors, nurses and pharmacy personnel responsible for the anti-
malarial treatment of young children were interviewed. P-ACT was used by 83% (95% confidence interval: 73-90%;
n = 59) as first-line treatment for young children. Use of 15 different P-ACT products was reported among which
only two have received WHO prequalification status and approval by a stringent registration authority. Use of a
specific P-ACT product was not linked to consumer prices or availability of supporting clinical trial data, but may
depend more on the marketing capacity of the manufacturer. Major differences in frequency and dosing of anti-
malarial regimens with identical anti-malarial compounds and the marketing of loose combinations were recorded.
Conclusion: Paediatric ACT is widely used for the treatment of uncomplicated malaria in young children. However,
the majority of P-ACT formulations in use do not meet highest international quality standards evoking concerns for
patients’ safety and the induction of drug resistance. Improving the quality of currently marketed P-ACT should
constitute a public health priority besides their adoption into official treatment recommendations.
Keywords: Artemisinin based combinations therapy, Paediatric drug formulation, Artemether, Lumefantrine, Amo-
diaquine, Dihydroartemisinin, Piperaquine, Mefloquine
Background
Several artemisinin combination therapies - the current
standard of care for the treatment of uncomplicated falci-
parum malaria - have been recently developed in the form
of paediatric formulations. These novel formulations com-
bine several advantages compared to the conventional
practice of crushing anti-malarial tablets for the treatment
of young children including improved swallow ability,
palatability, and more accurate dosing while maintaining
high efficacy [1-9]. Importantly, the tolerability of drug
administration was shown to be significantly improved in
the treatment of children as evidenced by lower rates of
drug induced vomiting and gastrointestinal disorders [10].
Based on this evidence, any paediatric artemisinin combi-
nation therapy (P-ACT) should have been taken up by
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tool to improve the management of uncomplicated
malaria in young children - the most important target
population suffering disproportionally from the burden of
malaria.
Interestingly, major barriers to the adoption of P-ACT
into national anti-malarial treatment policy in sub-Saharan
Africa have been reported according to a recent survey
[11,12]. Various reasons for this reluctance have been
cited by national health authorities including a lack of
effectiveness trials and unwillingness to diversify the pro-
duct portfolio of national procurement agencies due to dif-
ficulties in supply management. Whereas P-ACT may not
have been widely embraced by policy makers, little is
known about the availability and use of anti-malarial treat-
ments for young children in sub-Saharan Africa in the
field [13]. In this snapshot survey, the current practice of
anti-malarial treatment and the implementation of P-ACT
as therapeutic option for young children were investigated
in sentinel regions of sub-Saharan Africa.
Methods
A questionnaire based survey investigating the use of anti-
malarials for the treatment of young children was per-
formed in seven sub-Saharan Africa. At least one country
from West-, Central-, South, and East Africa where
malaria is endemic and ACT constitutes the current first-
line treatment for uncomplicated Plasmodium falciparum
malaria was selected.
Doctors, nurses and pharmacists representing urban
and rural areas as well as public and private sectors were
invited by an investigator to answer a structured ques-
tionnaire. Eligible persons were informed about the nat-
ure and the general objectives of the study. Oral consent
was obtained prior to the interview and information was
recorded on paper case record forms. Interviews were
conducted either face to face or on phone calls. Distinct
questionnaires were developed for professionals working
in clinical and pharmaceutical institutions in the coun-
try’s official language. The survey was designed to cover
the following topics: choice of first-line anti-malarial
treatment in routine practice for young children (<5
years of age), current availability of anti-malarial drugs
including trademarks and drug formulations, reasons for
preference of anti-malarials, and attitudes towards official
guidelines for the treatment of uncomplicated malaria.
Pharmacists’ questionnaires included questions about the
current availability and actual cost of P-ACT for the
patient and procurement procedures for anti-malarials.
Data were coded and entered into a purpose built elec-
tronic database (Microsoft Excel 2010, Microsoft, WA).
Descriptive univariate statistics were computed using a
commercially available software package (JMP 6.0, SAS).
Results
Seventy one health care professionals including 41 clini-
cians and 30 pharmacists participated in this survey from
August 2010 until July 2011. Respondents were repre-
senting 23 municipalities, including nine urban, eight
peri-urban and six rural localities in West- (Benin, Ivory
Coast, Togo; n = 29), Central (Congo Republic, Gabon; n
= 25), and South and East Africa (Mozambique, Uganda;
n = 17) Clinicians participating in this survey were doc-
tors and nurses responsible for the treatment of paedia-
tric patients in the primary, district and tertiary public
health care institutions (11, 13, and 17, respectively).
Approximately half of the clinicians additionally work in
private health care institutions. All pharmacists were
employed in private pharmacies.
Therapeutic options for the treatment of uncomplicated
malaria in young children
ACT was reported as first-line anti-malarial treatment
by all respondents (n = 71, 100%). ACT was cited as the
second- or third-line treatment by 66 (93%) health pro-
fessionals (not shown). Monotherapies including artesu-
nate, amodiaquine and halofantrine as well as
sulphadoxine-pyrimethamine combination were still
available and were used as an alternative second-line
treatment due to unavailability of ACT, mainly in rural
areas.
Overall, 59 (83%, 95% confidence intervals: 73-90%) par-
ticipants reported the use a P-ACT as the first-line drug
for the treatment of uncomplicated P. falciparum malaria
in young children (Tables 1 and 2). P-ACT formulations
were still used as second line anti-malarial by 48 (73%)
health professionals (Table 1).
Conventional tablet ACT was used by one fourth of
clinicians in public health facilities participating in this
survey as first line anti-malarials for the treatment of
uncomplicated malaria in young children (n = 10, 24%),
while all private pharmacists (n = 30, 100%) recommend
or deliver under clinicians’ prescription paediatric formu-
lations as first-line treatment.
The availability and use of 15 different P-ACT products
were reported by health professionals in this survey. The
product portfolio included syrup, oral suspension, disper-
sible tablets, and granule formulations. A minimum of
four formulations of P-ACT were listed by health profes-
sionals in Mozambique, and maximum of eight formula-
tions of P-ACT in Gabon and Togo. Two formulations of
P-ACT are not fixed-dose combinations and are mar-
keted as loose combinations (amodiaquine syrup and
artesunate granules). Among the 15 marketed combina-
tions eight products are combinations of artemether and
lumefantrine, representing 83% of the first-line P-ACT in
this survey. Coartem
® dispersible, a WHO prequalified
Agnandji et al. Malaria Journal 2011, 10:365
http://www.malariajournal.com/content/10/1/365
Page 2 of 6artemether-lumefantrine product, was given as first-
line treatment by 24% of health professionals. Artesu-
nate-amodiaquine was the second most used drug
combination as first-line P-ACT (n = 10, 14%). Dihy-
droartemisinin-piperaquine and artesunate-mefloquine
combinations were cited only as second- and third-line
treatments (Table 1). Syrup (or powder for oral suspen-
sion) drug formulation was overall the preferred choice
by health professionals followed by dispersible tablet
drug formulations (Table 2).
Dosing recommendations for identical anti-malarial
drug combinations varied markedly between different
products. Artemether-lumenfantrine was found mar-
keted as either a six-dose, three-day regimen, or as a
once daily three-day regimen. Similarly dosing per kilo-
gram bodyweight varied considerably between products
of different manufacturers (Additional file 1).
Regulatory status of P-ACT available on the market in
sub-Saharan Africa
Out of the 13 fixed dose formulations of P-ACT
reported in this survey, only Coartem
® dispersible
tablets (artemether-lumefantrine) and Coarsucam
® dis-
persible tablets (artesunate-amodiaquine) have received
WHO prequalification and in addition Coartem
®
Table 1 Anti-malarial drugs for the treatment of uncomplicated malaria in children: practices of health professionals
of 7 sub-Saharan- African countries
Anti-malarial First line treatment Second line treatment Third line treatment
Clinicians Pharmacists Clinicians Pharmacists Clinicians Pharmacists
N (%) N (%) N (%) N (%) N (%) N (%)
Paediatric ACT
AL 25 (61%) 24 (80%) 13 (34%) 12 (43%) 6 (25%) 11 (42%)
AS-AQ 6 (15%) 4 (13%) 11 (29%) 7 (25%) 1 (4%) 3 (12%)
AS-MQ
DHA-PPQ 2 (5%) 3 (11%) 1 (4%)
Total P-ACT 31 (76%) 28 (93%) 26 (68%) 22 (79%) 7 (29%) 15 (58%)
Tablets ACT
AL 7 (17%) 2 (7%) 1 (3%) 3 (11%) 2 (8%) 7 (26%)
AS-AQ 3 (7%) 3 (8%) 2 (8%) 1 (4%)
AS-MQ 2 (8%)
DHA-PPQ 2 (5%) 1 (3%) 2 (8%)
AS-S/P 1 (3%) 2 (7%)
Total T-ACT 10 (24%) 2 (7%) 7 (18%) 6 (21%) 8 (33%) 8 (30%)
Suppositories 1 (3%) 1 (4%)
Total ACT 41 (100%) 30 (100%) 34 (89%) 28 (100%) 15 (62%) 24 (92%)
Paediatric monotherapy 4 (11%) 2 (8%) 1 (4%)
Tablet monotherapy 5 (20%) 1 (4%)
Total non-ACT monotherapy 4 (11%) 7 (28%) 2 (8%)
Total respondents 41(100%) 30(100%) 38(100%) 28(100%) 24 (100) 26(100%
N absolute number of respondents
%: percentage related to the absolute numbers
ACT Artemisinin Combination Therapy
P-ACT Paediatric Artemisinin Combination Therapy
T-ACT Tablet Artemisinin Combination Therapies (adult drug formulation)
AL artemether-lumefantrine; AS artesunate; AQ amodiaquine; MQ mefloquine; DHA dihydroartemisinin; PPQ piperaquine; SP sulfadoxine-pyrimethamine; HF
halofantrine; QNN quinine
Clinicians: medical doctors and nurses
Table 2 Use of P-ACT in the treatment of uncomplicated
falciparum malaria in young children: practices of health
professionals of 7 sub-Saharan countries
Clinicians N(%) Pharmacists N(%)
Syrup, suspension 13(42%) 18(60%)
Dispersible tablet 16(52%) 8(27%)
Granules plus suspension 2(6%) 4(13%)
Total 31(100%) 30(100%)
N: absolute number
%: percentage
ACT: Artemisinin Combination Therapy
P-ACT: Paediatric Artemisinin Combination Therapy
T-ACT: Tablet Artemisinin Combination Therapy (adult like formulation)
Clinicians: medical doctors and nurses
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the FDA.
Sources of information for choices of anti-malarial
treatment
Health care personnel were asked for the primary sources
of information concerning the choice of anti-malarial
treatment. Here, national guidelines were cited most fre-
quently (n = 71, 100%). Medical representatives of phar-
maceutical companies were the second most frequently
cited source of information, particularly in urban and peri-
urban regions (n = 57, 80%). Few professionals (n = 8,
11%) used external sources, including scientific publica-
tions or personal experience as informed basis for the
decision for a first line anti-malarial.
Cost of P-ACT
In all seven countries anti-malarials should be free of
charge for children under five years of age, who are treated
in public health facilities according to the interviewed pro-
fessionals. In the private pharmacies interviewed in this
survey, the cost of P-ACT ranged from 0.8 to 8.5 Euros.
Dispersible tablets of artemether-lumefantrine and artesu-
nate-amodiaquine, available as blisters, were the cheapest
P-ACT (0.8-1.2 Euros for one treatment). Syrup, granules
and oral suspension formulations costs ranged from 5 to
8.5 Euros.
Discussion
This study was intended to provide an overview on the
current availability and use of P-ACT in Africa. Today, it
is known that official treatment recommendations and
national policies are slow in incorporating this novel tool
for the treatment and control of malaria. However, no
information is available on the actual availability of P-ACT
in sub-Saharan Africa, the current portfolio in this region,
and most importantly the current use of P-ACT in the
field.
This survey shows that P-ACT is used on a large-scale
in sub-Saharan Africa, both by clinicians and by pharma-
cists. A surprisingly high number of participants reported
the use of P-ACT as first-line treatment for young chil-
dren. Importantly, even second- and third-line treatment
constituted P-ACT in the majority of health care institu-
tions. The artemether-lumefantrine combination was the
most frequently prescribed P-ACT, accounting for 69% of
first-line treatments in the study population. The prefer-
ence of this ACT may be explained by multiple reasons.
Firstly, artemether-lumefantrine constitutes the recom-
mended first-line treatment in many African countries.
Secondly, there is the highest number of generic arte-
mether-lumefantrine combination products on the market
totalling up to eight brandmarks of P-ACT. Finally,
artemether-lumefantrine was the first internationally
registered P-ACT on the market and may, therefore, have
gained a competitive advantage and a larger market share.
A high degree of market penetration and availability of P-
ACT in sub-Saharan Africa has been shown in this survey.
All (n = 30) pharmacies reported the availability of at least
three different formulations of P-ACT. In Gabon, where
this survey was initiated and had most interviews, a total
of eight P-ACT brandmarks were available. Interestingly,
P-ACT was similarly available in larger cities as in smaller
communities in the interior provinces. These data show
that - despite the fact that P-ACT is not procured on a
large-scale by national procurement agencies - these drugs
are effectively distributed and marketed by the private
health care sector. Although, this study does not systema-
tically investigate the availability of anti-malarials in public
pharmacies, practices of health professionals working for
public sector indicate that non-prequalified P-ACT are
prescribed on a large scale in these institutions. In some
regions including Gabon national health insurance covers
and reimburses non-prequalified P-ACT prescribed to
patients at public hospitals and health centres.
The current portfolio of P-ACT encompasses various
kinds of child friendly drug formulations. Conventional
syrup and solution drug formulations are available on a
large-scale, as well as dispersible tablets, powder, and
granules. Whereas the availability of all paediatric drug
formulations is welcome, experts encourage the develop-
ment and use of non-liquid paediatric drug formulations
due to various considerations [14]. Stability of liquid
drug formulations is often limited - particularly in hot
climates - and production, distribution, and storage of
liquids is by far more challenging and expensive due to
higher volume and weight than dispersible tablet formu-
lations [15-19].
Importantly, dosing regimens of anti-malarial combi-
nation therapy varied between manufacturers. Whereas
artemether-lumefantrine tablets showed markedly
diminished efficacy in dosing regimens of less than six
intakes over three days, liquid artemether-lumefantrine
formulations are marketed as a once daily three-day
treatment (Additional file 1). Since there is lack of data
from high quality clinical trials for many of artemether-
lumefantrine products, differences in dosing strengths
and frequency raise important concerns. Importantly,
two forms of P-ACT are marketed as loose drug combi-
nations. This practice is contrary to current recommen-
dations, since loose drug combinations are associated
with reduced patient adherence and erroneous dosing.
Moreover, artesunate-monotherapy is included in these
products, a practice that is banned by the World Health
Organization due to considerations regarding the devel-
opment of artemisinin drug resistance. Given the high
number of alternative forms of P-ACT, the marketing of
these loose combinations seems not warranted.
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intending to conceal the intensely bitter taste of most
anti-malarial agents. This may be achieved by a drug for-
mulation produced to avoid any taste of the product or
by masking and adding a specific well appreciated fla-
vour. The reported product portfolio consists of a major-
ity of taste-masked products. Some exceptions, including
the WHO prequalified ASAQ (Sanofi-Aventis and
DNDi), are not taste-masked and exhibit, therefore, a bit-
ter taste. To our knowledge no data on the comparative
acceptability of various drug formulations in the treat-
ment of young children are available so far. It is unclear
whether specific forms of paediatric drug formulations or
whether taste-masking may improve the acceptability of
P-ACT and this should become an area of active research
in the future.
In this survey, it was also intended to elucidate reasons
for the choice of specific anti-malarials by health care pro-
viders. Reassuringly, national treatment recommendations
were cited as primary source in all regions. However, this
refers more to recommendations for combinations of anti-
malarial substances rather than for specific drug formula-
tions or specific products. This situation may explain why
P-ACT, although not specifically recommended by most
national treatment guidelines, is used on a large scale, and
also why some anti-malarial brands are used on a large
scale, even if not supported by clinical trial data. Impor-
tantly, medical representatives rank second as a source of
information and are by far more important than external
sources, including scientific publications and internet
resources. This situation seems problematic since balanced
information including quality and cost of P-ACT may not
be provided and artful marketing may be the decisive
advantage for or against the choice of an anti-malarial.
This survey is the first to address the issue of real world
use and availability of P-ACT in several sub-Saharan
Africa countries and was conducted to provide an over-
view on the current situation both for researchers as well
as for policy makers. Despite a surprisingly high coverage
and diversity of the market with P-ACT, inherent limita-
tions of this study need to be acknowledged. This survey
was not designed to provide representative data for all of
Africa, since more resources would have been necessary to
perform random sampling and high coverage in urban and
remote regions of all major African regions. Random sam-
pling was not performed and selection of participants was
influenced by their accessibility. It is, therefore, understood
that this survey may not accurately reflect subtle differ-
ences in treatment practices, at a regional and sub-regional
level, nor at public versus private health sectors. However,
this snapshot assessment of routine practices of health
care providers in sub-Saharan Africa has provided impor-
tant information about the current role of P-ACT in the
treatment of African children. Further data from surveys
with larger sample size are needed to strengthen the
answers gathered in this snapshot survey. Since no sys-
tematic information has been available so far, these data
may serve as valuable evidence for researchers and policy
makers alike.
Conclusions
In summary, P-ACT is used on a large scale in sub-
Saharan Africa and availability of various brands is sur-
prisingly high. However, quality issues of distinct formu-
lations of P-ACT are underappreciated by health care
providers and resources are often diverted to the pur-
chase and use of products without sufficient clinical evi-
dence. Objective guidance to support the choice of the
selected P-ACT is necessary for both national authori-
ties and health care personnel.
Additional material
Additinal file 1: P-ACT listed by health professionals in 7 sub-
Saharan countries: trademarks, formulations, regimen, daily dosage
and regulatory status.
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